Mesoblast Limited (ASX:MSB – Get Free Report) insider Gregory George bought 74,621 shares of the business’s stock in a transaction that occurred on Monday, March 10th. The stock was bought at an average price of A$12.88 ($8.20) per share, with a total value of A$961,118.48 ($612,177.38).
Gregory George also recently made the following trade(s):
- On Monday, March 3rd, Gregory George purchased 5,034,129 shares of Mesoblast stock. The shares were purchased at an average cost of A$2.95 ($1.88) per share, with a total value of A$14,830,544.03 ($9,446,206.39).
Mesoblast Stock Performance
The stock has a market cap of $2.32 billion, a P/E ratio of -23.29, a PEG ratio of 9.56 and a beta of 2.38. The company has a debt-to-equity ratio of 24.76, a current ratio of 1.18 and a quick ratio of 1.82.
About Mesoblast
Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.
Read More
- Five stocks we like better than Mesoblast
- Earnings Per Share Calculator: How to Calculate EPS
- What GTC 2025 Signals for NVIDIA Stock’s Next Big Move
- How to Invest in Small Cap Stocks
- Alphabet’s Officially In A Bear Market—Time To Buy?
- Manufacturing Stocks Investing
- D-Wave and Quantum Supremacy: Implications For Investors
Receive News & Ratings for Mesoblast Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mesoblast and related companies with MarketBeat.com's FREE daily email newsletter.
